http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2752595-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_91c139f8783cb8c8ee5f11828c0067c5 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-755 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-224 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-9645 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 |
| filingDate | 2015-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b342a9534e113716f9a416b16b1e23a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f9088e24fa39840337c9e6804dea9de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f549b87b4b15535e879f4c948b1f962 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_956636fc2edf07c10022c3af38b277cc |
| publicationDate | 2021-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2752595-C2 |
| titleOfInvention | Method for measuring reactivity of fviii |
| abstract | FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and applies to a method for measuring reactivity of coagulation factor VIII, wherein the method includes a stage wherein (1) a sample produced from blood, containing a substance exhibiting activity relative to functional replacement of coagulation factor VIII, wherein the substance is a bispecific antibody binding with coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated blood coagulation factor X, is brought into contact with (2) one or several substances neutralising a substance exhibiting activity relative to functional replacement of coagulation factor VIII, wherein one or more neutralising substances constitutes one or several substances selected from the group consisting of peptides, polypeptides, organic compounds, aptamers and antibodies neutralising a substance exhibiting activity relative to functional replacement of coagulation factor VIII; followed by measuring reactivity of the coagulation factor by measuring activity of coagulation factor VIII or a coagulation factor VIII inhibitor titre. The group of inventions also relates to a set containing antibodies for use in the described method; an application of the described method for diagnosing the severity of a hemorrhagic disease in an individual.EFFECT: group of inventions ensures accurate estimation of activity of FVIII in the plasma of a patient with hemophilia A using an APTT-based one-stage coagulation assay and, additionally, accurate estimation of the FVIII inhibitor titre in the plasma of a patient with hemophilia A with an FVIII inhibitor, using an APTT-based Bethesda assay.16 cl, 4 dwg, 4 tbl, 6 ex |
| priorityDate | 2014-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1175.